A Phase 4 interventional study of Pramipexole and Placebo in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 39 sites in United States. Open to participants aged 31 Years and older. Per ClinicalTrials.gov, last updated 2014-05-16.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 10th largest by enrollment, is one of 5 that started in 2006, is one of 10 in phase 4, and was the 8th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 31 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 312 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2006, is one of 7 in phase 4, and was the 9th registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective: to assess the efficacy of pramipexole given two times daily compared to placebo.
Secondary objectives: to assess the effects of pramipexole on mood, cognition, fatigue, impulse control, daytime sleepiness and nighttime sleep compared to placebo; to compare the tolerability among the treatment groups over 12 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Potential subjects must meet all of the following inclusion criteria to be eligible for enrollment into this study:
Exclusion Criteria:
Individuals with any of the following characteristics will not be eligible for entry into this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Pramipexole 0.5 mg tid (three times a day)
Drug: Pramipexole
Pramipexole 0.5 mg bid (bis in die (two times a day))
Drug: Pramipexole
Pramipexole 0.75 mg bid (bis in die (two times a day))
Drug: Pramipexole
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Total score ranges from zero (best) to 176 (worst), as the sum of Parts I (Mental questions), II (Activity of Daily Living questions), and III (Motor examination)
Time frame: From baseline to week 12
Modified Hoehn and Yahr Stage
Score ranges from best 0 (no signs of disease) to worst 5 (wheelchair bound or bedridden unless aided)
Time frame: From baseline to week 12
Epworth Sleepiness Scale
Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)
Time frame: From baseline to week 12
Beck Depression Inventory II
Total score ranges from zero (best) to 63 (worst); scale has 21 items, each rated from zero (absent) to 3 (severe)
Time frame: From baseline to week 12
| Milestone | Placebo | Mirapex (Pramipexole 0.5 mg Tid) | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) |
|---|---|---|---|---|
| Started | 77 | 80 | 81 | 73 |
| Completed | 72 | 70 | 70 | 62 |
| Not completed | 5 | 10 | 11 | 11 |
| Withdrew: Adverse event | 1 | 7 | 9 | 9 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 | 2 |
| Withdrew: Worsening of disease under study | 2 | 0 | 0 | 0 |
| Withdrew: Worsening of other pre-existing disease | 0 | 1 | 0 | 0 |
Total score ranges from zero (best) to 176 (worst), as the sum of Parts I (Mental questions), II (Activity of Daily Living questions), and III (Motor examination)
| units on a scale | Placebo | Mirapex (Pramipexole 0.5 mg Tid) | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) |
|---|---|---|---|---|
| UPDRS at baseline | 28.97 ± 11.82 | 27.66 ± 10.72 | 27.21 ± 11.76 | 27.77 ± 9.18 |
| UPDRS at week 12 | 28.19 ± 12.94 | 22.92 ± 10.44 | 22.96 ± 11.94 | 22.65 ± 10.82 |
Score ranges from best 0 (no signs of disease) to worst 5 (wheelchair bound or bedridden unless aided)
| units on a scale | Placebo | Mirapex (Pramipexole 0.5 mg Tid) | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) |
|---|---|---|---|---|
| Modified Hoehn and Yahr Stage at baseline | 1.81 ± 0.48 | 1.74 ± 0.5 | 1.72 ± 0.5 | 1.73 ± 0.51 |
| Modified Hoehn and Yahr Stage at week 12 | 1.74 ± 0.54 | 1.68 ± 0.52 | 1.69 ± 0.52 | 1.62 ± 0.56 |
Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)
| units on a scale | Placebo | Mirapex (Pramipexole 0.5 mg Tid) | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) |
|---|---|---|---|---|
| Epworth Sleepiness Scale at baseline | 5.29 ± 3.47 | 5.8 ± 3.66 | 5.78 ± 3.74 | 6.34 ± 4.35 |
| Epworth Sleepiness Scale at week 12 | 5.09 ± 3.33 | 6.58 ± 3.62 | 6.44 ± 4.21 | 7.52 ± 5.03 |
Total score ranges from zero (best) to 63 (worst); scale has 21 items, each rated from zero (absent) to 3 (severe)
| units on a scale | Placebo | Mirapex (Pramipexole 0.5 mg Tid) | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) |
|---|---|---|---|---|
| Beck Depression Inventory II at baseline | 6.05 ± 6.01 | 6.66 ± 5.36 | 6.96 ± 5.14 | 7.4 ± 5.87 |
| Beck Depression Inventory II at week 12 | 5.92 ± 5.83 | 5.70 ± 5.14 | 5.97 ± 5.14 | 6.54 ± 5.19 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/77 (0%) | 27/77 (35.1%) |
| Mirapex (Pramipexole 0.5 mg Bid) | — | 0/81 (0%) | 42/81 (51.9%) |
| Mirapex (Pramipexole 0.75 mg Bid) | — | 2/73 (2.7%) | 37/73 (50.7%) |
| Mirapex (Pramipexole 0.5 mg Tid) | — | 1/80 (1.3%) | 43/80 (53.8%) |
| Event | Placebo | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) | Mirapex (Pramipexole 0.5 mg Tid) |
|---|---|---|---|---|
| Coronary Artery DiseaseCardiac disorders | 0/77 | 0/81 | 1/73 | 0/80 |
| Cerebral Infarction, HemiparesisNervous system disorders | 0/77 | 0/81 | 1/73 | 0/80 |
| ileus (patient stopped drugs 2 days prior)Gastrointestinal disorders | 0/77 | 0/81 | 0/73 | 1/80 |
| Event | Placebo | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) | Mirapex (Pramipexole 0.5 mg Tid) |
|---|---|---|---|---|
| somnolenceNervous system disorders | 4/77 | 14/81 | 16/73 | 20/80 |
| nauseaGastrointestinal disorders | 7/77 | 18/81 | 11/73 | 15/80 |
| insomniaPsychiatric disorders | 4/77 | 3/81 | 9/73 | 5/80 |
| dizzinessNervous system disorders | 7/77 | 9/81 | 5/73 | 9/80 |
| headacheNervous system disorders | 8/77 | 7/81 | 6/73 | 4/80 |
| constipationGastrointestinal disorders | 2/77 | 8/81 | 7/73 | 5/80 |
| fatigueGeneral disorders | 3/77 | 6/81 | 7/73 | 4/80 |
| abnormal dreamsPsychiatric disorders | 3/77 | 3/81 | 2/73 | 5/80 |
| oedema peripheralGeneral disorders | 0/77 | 2/81 | 4/73 | 3/80 |
| tremorNervous system disorders | 4/77 | 1/81 | 3/73 | 0/80 |
| Age, Continuous(years) | Placebo | Mirapex (Pramipexole 0.5 mg Tid) | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) | Total |
|---|---|---|---|---|---|
| Mean | 60.7 ± 11 | 63.7 ± 9.8 | 61.6 ± 10.2 | 63.1 ± 9.9 | 62.3 ± 10.2 |
| Sex: Female, Male(Participants) | Placebo | Mirapex (Pramipexole 0.5 mg Tid) | Mirapex (Pramipexole 0.5 mg Bid) | Mirapex (Pramipexole 0.75 mg Bid) | Total |
|---|---|---|---|---|---|
| Female | 19 | 23 | 30 | 32 | 104 |
| Male | 58 | 57 | 51 | 41 | 207 |
The record gives a start of Nov 2006 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole